<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794543</url>
  </required_header>
  <id_info>
    <org_study_id>2020-028-PBRC</org_study_id>
    <secondary_id>U54GM104940</secondary_id>
    <nct_id>NCT04794543</nct_id>
  </id_info>
  <brief_title>Effects of Using E-Cigarettes on Lungs in People With HIV (HBS Ancillary)</brief_title>
  <acronym>HBS Ancillary</acronym>
  <official_title>Effects of E-Cigarettes on the Lung Metabolome in People Living With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an ancillary study, thus participants will be recruited from participants in the HBS&#xD;
      Study. This project assesses the role of the e-cigarettes and vaping on lung health. The&#xD;
      proposed work will inform the design of future studies to better understand vaping's health&#xD;
      consequences and to test novel interventions to mitigate vaping's contribution to acute&#xD;
      and/or chronic lung injury.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in respiratory tract metabolite profiles in PLWH</measure>
    <time_frame>Baseline only (at Visit 1)</time_frame>
    <description>Metabolomic analyses of exhaled breath condensate and gas.</description>
  </primary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hiv</condition>
  <condition>Lung Injury</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      breath samples, blood, stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People living with HIV (PLWH) in the study site areas who are enrolled in the HBS study&#xD;
        (main trial).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        This project is an ancillary study to the HBS Study. Inclusion Criteria for that IRB&#xD;
        approved study are:&#xD;
&#xD;
          -  documented HIV-infection&#xD;
&#xD;
          -  in care at an HIV specialty clinic&#xD;
&#xD;
          -  age â‰¥ 18 years.&#xD;
&#xD;
        Exclusion criteria for the HBS Study are:&#xD;
&#xD;
          -  a pacemaker or other implanted electronic device&#xD;
&#xD;
          -  pregnant women, prisoners, cognitively-impaired subjects.&#xD;
&#xD;
        For this ancillary, the experimental group must actively use e-cigarettes or vape. The&#xD;
        control group will have no use of e-cigarettes or vape or active smoking in the past year.&#xD;
&#xD;
        Participants must be willing to archive data and biological samples for future use.&#xD;
&#xD;
        Exclusion from the ancillary are:&#xD;
&#xD;
          -  active combustible cigarette users&#xD;
&#xD;
          -  overt respiratory or oral cavity disease&#xD;
&#xD;
          -  acute illness in the past 4 weeks&#xD;
&#xD;
          -  active cancer&#xD;
&#xD;
          -  active weight loss program&#xD;
&#xD;
          -  any other medical, psychiatric or behavioral factors that, in the judgment of the PI&#xD;
             may interfere with study participation or ability to follow the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Apolzan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Project Manager</last_name>
    <phone>225-763-0939</phone>
    <email>callie.hebert@pbrc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Project Manager</last_name>
      <phone>225-763-0939</phone>
      <email>jenny.ricks@pbrc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lsuhsc-No</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Project Manager</last_name>
    </contact>
    <investigator>
      <last_name>David Welsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>John Apolzan</investigator_full_name>
    <investigator_title>Assistant Professor, Director Clinical Nutrition and Metabolism Lab</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

